Taysha Gene Therapies Operating Margin 2020-2025 | TSHA
Current and historical operating margin for Taysha Gene Therapies (TSHA) over the last 10 years. The current operating profit margin for Taysha Gene Therapies as of March 31, 2025 is -1177.51%.
| Taysha Gene Therapies Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2025-03-31 |
$0.01B |
$-0.09B |
-1257.14% |
| 2024-12-31 |
$0.01B |
$-0.09B |
-1137.50% |
| 2024-09-30 |
$0.01B |
$-0.09B |
-870.00% |
| 2024-06-30 |
$0.01B |
$-0.08B |
-592.31% |
| 2024-03-31 |
$0.01B |
$-0.08B |
-564.29% |
| 2023-12-31 |
$0.02B |
$-0.07B |
-450.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.511B |
$0.008B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
